The filing is for the offer and resale from time to time of up to 10.625M ordinary shares or up to 8.5M American Depositary Shares, ADSs, each representing one and one quarter ordinary shares, by the selling shareholder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene says first patient dosed in Phase 2 study of muzastotug, KEYTRUDA
- Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment
- Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology
- Adagene initiated with a Buy at Lucid Capital
- Adagene expands SAFEbody collaboration, license agreement with Exelixis